Cargando…
Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors
Clinical research for patients with rare cancers has been very challenging. First and foremost, patient accrual to clinical trials typically requires a network, cooperative group, or even international collaboration in order to achieve the necessary numbers of patients to adequately evaluate a new t...
Autores principales: | Armstrong, Terri S, Gilbert, Mark R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561126/ https://www.ncbi.nlm.nih.gov/pubmed/34725696 http://dx.doi.org/10.1093/neuonc/noab209 |
Ejemplares similares
-
Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
por: Barnes, Christopher J., et al.
Publicado: (2013) -
PEDT-5 Problem for the guideline of CNS germ cell tumors
por: Nakamura, Hideo, et al.
Publicado: (2021) -
MPC-17 2021 WHO Classification of Tumors of the CNS, 5th ed
por: Komori, Takashi
Publicado: (2021) -
Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials
por: Kim, Yeonju, et al.
Publicado: (2023) -
57. CIRCULATING TUMOR CELLS (CTC) IN CEREBROSPINAL FLUID (CSF) AS A PREDICTOR OF SURVIVAL IN CNS METASTASES
por: Diaz, Maria, et al.
Publicado: (2020)